The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Die EMA hat gestern nach einer Neubewertung eine beschränkte Zulassung für das umstrittene Medikament erlassen. Noch sind ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

In July 2023, the U.S. FDA fully approved Leqembi for adults with Alzheimer's disease, and subsequently, the companies launched the product in the U.S. for $26.5K. The drug later rolled out in ...

Dr Patrik Holler, director of the Oncology Business Group at Eisai GmbH, said: “Eisai cannot understand the suggestion of the IQWIG that no additional benefit has been proven for eribulin ...

Future of Healthcategory Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest July 30, 2024 Businesscategory Shares of Japan's Eisai tumble after EU rejects ...

STOCKHOLM, Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...

This research was funded by Eisai GmbH, Germany. Eisai GmbH was informed throughout the process of data collection and analyses, and contributed to the research through critical review of results ...

Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...

Dr Patrik Holler, director of the Oncology Business Group at Eisai GmbH, said: “Eisai cannot understand the suggestion of the IQWIG that no additional benefit has been proven for eribulin ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...